复发多发性骨髓瘤蛋白酶体抑制剂治疗期间心脏事件的前瞻性研究
这项前瞻性、观察性、多中心研究纳入95例接受卡非佐米或硼替佐米治疗的复发多发性骨髓瘤患者,中位随访25个月。卡非佐米组心脏事件发生率为51%,硼替佐米组为17%(P = .002),中位首次事件时间为31天,86%发生在治疗前3个月内。基线或治疗早期利钠肽升高与心脏事件风险显著增加相关,发生心脏事件者无进展生存和总生存更差。
要点
- 卡非佐米组心脏事件发生率51%,硼替佐米组17%(P = .002)。
- 中位首次心脏事件时间为31天,86%发生在治疗前3个月内。
- 基线BNP>100 pg/mL或NT-proBNP>125 pg/mL者OR为10.8(P < .001)。
核心结论
- 蛋白酶体抑制剂治疗复发多发性骨髓瘤期间心脏事件常见,尤其卡非佐米治疗者,多发生在治疗前3个月内。
- 心脏事件与更差的无进展生存(log-rank P = .01)和总生存(log-rank P < .001)相关。
- 利钠肽对心脏事件有高度预测价值,但在常规纳入卡非佐米治疗患者管理前需验证。
研究设计与样本
- 前瞻性、观察性、多中心研究,纳入95例接受卡非佐米(65例)或硼替佐米(30例)治疗的复发多发性骨髓瘤患者。
- 基线及6个月内定期评估心脏生物标志物(肌钙蛋白I或T、BNP、NT-proBNP)、心电图和超声心动图,监测心脏事件18个月,中位随访25个月。
主要发现
- 卡非佐米组心脏事件发生率为51%,硼替佐米组为17%(P = .002)。
- 中位首次心脏事件时间为治疗开始后31天,86%发生在治疗前3个月内。
- 卡非佐米治疗者基线BNP>100 pg/mL或NT-proBNP>125 pg/mL与心脏事件风险增加相关(OR 10.8;P < .001)。
- 卡非佐米治疗第一周期中期出现利钠肽升高与心脏事件风险显著增高相关(OR 36.0;P < .001)。
关键数值与推荐
- 基线BNP>100 pg/mL或NT-proBNP>125 pg/mL:OR 10.8(P < .001)。
- 卡非佐米治疗第一周期中期利钠肽升高:OR 36.0(P < .001)。
- 89%的患者可安全恢复蛋白酶体抑制剂治疗,41%需调整化疗方案。
临床怎么用
- 卡非佐米治疗复发多发性骨髓瘤时心脏事件常见,尤其治疗前3个月内需监测。
- 利钠肽(BNP/NT-proBNP)对心脏事件有高度预测价值,但需验证后方可常规纳入卡非佐米治疗患者管理。
- 发生心脏事件后多数患者可安全恢复蛋白酶体抑制剂治疗,部分需调整化疗方案。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Cardiovascular adverse events (CVAEs) can occur during proteasome inhibitor (PI) therapy. We conducted a prospective, observational, multi-institutional study to define risk factors and outcomes in patients with multiple myeloma (MM) receiving PIs. PATIENTS AND METHODS: Patients with relapsed MM initiating carfilzomib- or bortezomib-based therapy underwent baseline assessments and repeated assessments at regular intervals over 6 months, including cardiac biomarkers (troponin I or T, brain natriuretic peptide [BNP], and N-terminal proBNP), ECG, and echocardiography. Monitoring occurred over 18 months for development of CVAEs. RESULTS: Of 95 patients enrolled, 65 received carfilzomib and 30 received bortezomib, with median 25 months of follow-up. Sixty-four CVAEs occurred, with 55% grade 3 or greater in severity. CVAEs occurred in 51% of patients treated with carfilzomib and 17% of those treated with bortezomib (P = .002). Median time to first CVAE from treatment start was 31 days, and 86% occurred within the first 3 months. Patients receiving carfilzomib-based therapy with a baseline elevated BNP level higher than 100 pg/mL or N-terminal proBNP level higher than 125 pg/mL had increased risk for CVAE (odds ratio, 10.8; P < .001). Elevated natriuretic peptides occurring mid-first cycle of treatment with carfilzomib were associated with a substantially higher risk of CVAEs (odds ratio, 36.0; P < .001). Patients who experienced a CVAE had inferior progression-free survival (log-rank P = .01) and overall survival (log-rank P < .001). PI therapy was safely resumed in 89% of patients, although 41% required chemotherapy modifications. CONCLUSION: CVAEs are common during PI therapy for relapsed MM, especially with carfilzomib, particularly within the first 3 months of therapy. CVAEs were associated with worse overall outcomes, but usually, discontinuation of therapy was not required. Natriuretic peptides were highly predictive of CVAEs; however, validation of this finding is necessary before uniform incorporation into the routine management of patients receiving carfilzomib.
引用
- Cornell RF, Ky B, Weiss BM, et al. Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma. J Clin Oncol. 2019. PMID: 31188726. doi:10.1200/JCO.19.00231
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。